A 45-year-old man with Graves' disease has been on methimazole 30 mg daily for 8 weeks. His TSH is now 2.5 mIU/L and free T4 is 12 pmol/L (normal range). However, he develops a maculopapular rash and mild arthralgia. Which of the following is the most appropriate next step in management?

Explanation

## Management of Antithyroid Drug Adverse Effects ### Clinical Scenario Analysis This patient has achieved euthyroidism (TSH 2.5, free T4 normal) on methimazole but has developed a rash and arthralgia—common, mild adverse effects of methimazole that do NOT mandate immediate drug discontinuation. ### Why Block-and-Replace (Option C) Is Optimal **Key Point:** Methimazole-induced rash and arthralgia are dose-related, reversible adverse effects. The appropriate management is to reduce the antithyroid dose while preventing relapse into hyperthyroidism by adding levothyroxine—the "block-and-replace" regimen. **High-Yield:** Block-and-replace strategy: 1. Reduce methimazole to a lower maintenance dose (10–15 mg daily) 2. Add levothyroxine (50–100 μg daily) to maintain euthyroidism 3. This minimizes antithyroid drug exposure while preventing hypothyroidism and relapse ### Mechanism of Methimazole Adverse Effects | Adverse Effect | Incidence | Severity | Management | |---|---|---|---| | **Rash (maculopapular)** | 5–10% | Mild; dose-related | Reduce dose; may resolve with continued use | | **Arthralgia** | 1–5% | Mild; dose-related | Reduce dose; NSAIDs if needed | | **Agranulocytosis** | 0.1–0.5% | **Severe; life-threatening** | Immediate discontinuation; requires urgent CBC | | **Hepatitis** | <0.1% | Severe | Immediate discontinuation; LFTs | | **ANCA-associated vasculitis** | Rare | Severe | Discontinue; consider immunosuppression | **Clinical Pearl:** Rash and arthralgia are NOT harbingers of agranulocytosis or hepatotoxicity; they are mild, dose-dependent reactions that often resolve with dose reduction or continued use. Agranulocytosis and hepatitis are idiosyncratic (dose-independent) and require immediate drug cessation. **Mnemonic:** **HARM = Hepatitis, Agranulocytosis, Rash, Myalgia** — but only H and A mandate immediate discontinuation; R and M respond to dose reduction. [cite:KD Tripathi 8e Ch 54] ## Why Other Options Are Incorrect **Option A (Continue + antihistamines):** While rash may respond to antihistamines, this does not address the underlying problem—continued high-dose methimazole exposure. Dose reduction is more effective and prevents further adverse effects. **Option B (Switch to PTU):** This is unnecessary. Methimazole rash is not an early sign of hepatotoxicity (which is idiosyncratic and rare). Switching to PTU exposes the patient to a different drug with its own hepatotoxicity risk. Cross-reactivity between methimazole and PTU is rare (~25%), so switching is not routinely indicated for simple rash. **Option D (Iodine solution):** Iodine is NOT suitable for long-term maintenance therapy. It loses efficacy within 10–14 days (escape phenomenon) and is reserved for thyroid storm or pre-operative preparation. Using it as maintenance therapy would result in relapse.